AbbVie's Upadacitinib Aces Another Arthritis Trial, But Safety Concerns Linger

AbbVie says safety results for the JAK1 inhibitor upadacitinib in SELECT-MONOTHERAPY study were in line with the rheumatoid arthritis population, but some analysts are concerned about the drug's cardiovascular profile, especially compared with Pfizer's first-in-class Xeljanz.